Aterian, Inc. (ATER) Tops Q3 EPS by 6c

Aterian, Inc. (NASDAQ: ATER) reported Q3 EPS of ($0.08), $0.06 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $39.7 million versus the consensus estimate of $34.26 million.

For earnings history and earnings-related data on Aterian, Inc. (ATER) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c